Galapagos NV logo
Galapagos NV GLPG
report update icon

Quarterly report 2025-Q4
added 05-06-2026

Galapagos NV Income Statement 2025-2011 | GLPG

Brief overview of financial performance at Galapagos NV

The conclusions below are based on five years of reported results. Revenue at Galapagos NV moved from 478 million euros in 2020 to 1.1 billion euros in 2025. The five-year change reached +132.7%, while CAGR stood at 18.4%. The pace indicates confident and sustained business growth.

EBITDA was −179 million euros at the beginning and 351 million euros at the end of the period (+296.4%). EBITDA expanded faster than the top line. The EBITDA share of revenue changed from −37.4% to 31.5%. The business generated more EBITDA from each unit of revenue.

The final result was −305 million euros initially and 321 million euros in the final year. The trajectory reversed from a loss to positive earnings.

Market value was 6.8 billion euros at the start and 1.9 billion euros at the end. Financial performance is stronger than the share-price trend.

Financial takeaway

The results present an uneven picture without one dominant signal. Key strengths include improving net profitability, positive operating leverage and sales growth. The main areas of concern are a weaker market valuation. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Galapagos NV

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.91 B 1.57 B 2.12 B 2.82 B 4.42 B 6.79 B 12.8 M 5.35 B 5.85 B 60.7 B 1.75 B 618 M 702 M 653 M -

Shares

65.9 M 65.9 M 65.9 M 65.7 M 65.5 M 65.1 M 57.6 K 52.1 M 49.5 M 944 M 35.7 M 30.1 M 28.8 M 26.5 M -

Historical Prices

28.9 23.8 32.2 42.9 67.5 104 223 103 118 65.1 48.9 20.5 24.3 24.1 -

Net Income

321 M 74.1 M 212 M -218 M -103 M -305 M 150 M -29.2 M -116 M 54.2 M -118 M 33.2 M -8.08 M -5.72 M -33.1 M

Revenue

1.11 B 276 M 240 M 241 M 234 M 478 M 835 M 289 M 127 M 152 M 39.6 M 69.4 M 138 M 136 M 95.9 M

Cost of Revenue

29.7 M 34.9 M - 12.1 M 1.63 M - - - - - - - - - -

Gross Profit

- - - - - - 896 M 318 M 156 M 152 M -90.2 M -41.7 M 96.4 M 88.1 M -29.1 M

Operating Income

295 M -188 M -88.3 M -131 M -166 M -179 M 369 M -47.1 M -89.8 M -11.5 M -89.4 M - - - -

Interest Expense

1.03 M 911 K 1.77 M 6.88 M 11.6 M 9.39 M 1.27 M 780 K 936 K 47 K 46 K - - - -

EBITDA

351 M -143 M -44.6 M -65.5 M -166 M -179 M 369 M -47.1 M -89.8 M 57.3 M -86 M -31.3 M -8.18 M -749 K -20.8 M

Operating Expenses

- - - - - 709 M 526 M 363 M 246 M 1.44 M 167 M 168 M 227 M 205 M 3.84 M

General and Administrative Expenses

147 M 117 M 128 M 135 M 141 M 95.7 M -49.1 M -31.5 M -21.6 M -20 M 19.1 M 13.9 M 24.5 M 23.2 M 23.1 M

All numbers in EUR currency

Quarterly Income Statement Galapagos NV

2025-Q4 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

65.9 M 65.9 M 65.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

321 M 74.1 M 212 M - - - - - - -64.3 M - - - -115 M - - - -47.2 M - - - -21.8 M - - - -35.6 M - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

1.11 B 276 M 240 M - - - - - - 140 M - - - 99.6 M - - - 58.7 M - - - 49.7 M - - - 26.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

29.7 M 34.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

295 M -188 M -88.3 M - - - - - - -46.8 M - - - -88.2 M - - - -44.4 M - - - -33.8 M - - - -21.7 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

1.03 M 911 K 1.77 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

351 M -143 M -44.6 M - - - - - - -46.8 M - - - -88.2 M - - - -44.4 M - - - -33.8 M - - - -21.7 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - 200 M - - - 202 M - - - 112 M - - - 90.8 M - - - 54.8 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

147 M 117 M 128 M - - - - - - 46.4 M - - - 37.3 M - - - 13.7 M - - - 8.5 M - - - 6.33 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

The income statement is one of the three key financial reports of a company Galapagos NV (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Revolution Medicines Revolution Medicines
RVMD
$ 207.32 0.24 % $ 39.4 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 101.8 0.08 % $ 6.62 B usaUSA
Rezolute Rezolute
RZLT
$ 4.4 0.88 % $ 334 M usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 3.45 0.77 % $ 874 M usaUSA
Seer Seer
SEER
$ 1.95 0.26 % $ 108 M usaUSA
Precigen Precigen
PGEN
$ 6.87 0.14 % $ 2.15 B usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.2 1.86 % $ 229 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 19.94 0.05 % $ 1.73 B usaUSA
Soligenix Soligenix
SNGX
$ 0.38 1.18 % $ 1.97 M usaUSA
Spruce Biosciences Spruce Biosciences
SPRB
$ 59.09 2.0 % $ 45.3 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 20.94 0.04 % $ 2.1 B usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 30.05 0.81 % $ 1.78 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 19.1 0.34 % $ 162 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 6.5 0.29 % $ 452 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 42.43 0.23 % $ 2.4 B usaUSA
Savara Savara
SVRA
$ 5.53 2.98 % $ 1.23 B usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.24 0.45 % $ 1.52 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.32 1.49 % $ 28.9 B japanJapan
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.31 0.01 % $ 11.3 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.98 2.06 % $ 77.7 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 36.76 1.21 % $ 42.1 B israelIsrael
TG Therapeutics TG Therapeutics
TGTX
$ 55.74 0.58 % $ 8.04 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 16.82 1.17 % $ 2.27 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 5.48 0.54 % $ 1.75 B usaUSA
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 69.37 0.35 % $ 193 M israelIsrael
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 43.82 0.02 % $ 2.11 B israelIsrael
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 497.97 2.12 % $ 22.1 B usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.19 0.41 % $ 66.7 M usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 57.42 3.78 % $ 6.59 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
NextCure NextCure
NXTC
$ 8.42 7.67 % $ 23.9 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 5.26 0.75 % $ 56 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 23.17 1.09 % $ 2.36 B usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 528.9 0.22 % $ 135 B usaUSA
Verastem Verastem
VSTM
$ 8.08 0.55 % $ 560 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 32.79 0.03 % $ 130 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 3.4 3.85 % $ 200 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 4.91 1.03 % $ 828 M singaporeSingapore
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 13.16 0.15 % $ 112 M usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 4.28 0.86 % $ 7.28 M usaUSA
XBiotech XBiotech
XBIT
$ 2.18 0.23 % $ 66.5 M usaUSA
Exicure Exicure
XCUR
$ 1.41 12.8 % $ 8.88 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 59.55 0.18 % $ 4.72 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 8.48 0.12 % $ 1.36 B usaUSA